Changchun high-tech subsidiary gets nod for growth hormone drug clinical trials

Changchun High & New Technology Industry Group announced today that its subsidiary, Changchun GeneScience Pharmaceuticals, has received acceptance for its clinical trial application for GS3-007a dry powder for oral suspension. This novel Class 1 chemical drug, developed independently by GeneScience Pharmaceuticals, is intended to treat growth retardation in children caused by endogenous growth hormone deficiency (PGHD).

GS3-007a is an orally administered small molecule that stimulates growth hormone secretion, offering an alternative to currently approved injectable treatments for Pediatric Growth Hormone Deficiency (PGHD). The drug aims to address the unmet needs of short-statured children requiring growth promotion.

With PGHD affecting approximately 1 in 8,600 children in China, and an estimated 230,000 diagnosed cases among 5.1m short-statured children, the market for this treatment is significant. The company will actively advance this research project, though it cautions investors about potential risks given the long and complex nature of drug development.